- Home
- FGI vs RNAZ Comparison
FGI vs RNAZ Comparison
Compare FGI & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGI
- RNAZ
- Stock Information
- Founded
- FGI 1987
- RNAZ 2016
- Country
- FGI United States
- RNAZ United States
- Employees
- FGI N/A
- RNAZ N/A
- Industry
- FGI Industrial Specialties
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- FGI Industrials
- RNAZ Health Care
- Exchange
- FGI Nasdaq
- RNAZ Nasdaq
- Market Cap
- FGI 6.6M
- RNAZ 6.1M
- IPO Year
- FGI 2022
- RNAZ 2021
- Fundamental
- Price
- FGI $0.60
- RNAZ $7.97
- Analyst Decision
- FGI
- RNAZ Strong Buy
- Analyst Count
- FGI 0
- RNAZ 1
- Target Price
- FGI N/A
- RNAZ $280.00
- AVG Volume (30 Days)
- FGI 230.6K
- RNAZ 32.8K
- Earning Date
- FGI 08-06-2025
- RNAZ 08-13-2025
- Dividend Yield
- FGI N/A
- RNAZ N/A
- EPS Growth
- FGI N/A
- RNAZ N/A
- EPS
- FGI N/A
- RNAZ N/A
- Revenue
- FGI $134,277,102.00
- RNAZ N/A
- Revenue This Year
- FGI $7.72
- RNAZ N/A
- Revenue Next Year
- FGI $6.94
- RNAZ N/A
- P/E Ratio
- FGI N/A
- RNAZ N/A
- Revenue Growth
- FGI 11.13
- RNAZ N/A
- 52 Week Low
- FGI $0.46
- RNAZ $6.15
- 52 Week High
- FGI $1.36
- RNAZ $970.20
- Technical
- Relative Strength Index (RSI)
- FGI 49.90
- RNAZ 47.04
- Support Level
- FGI $0.56
- RNAZ $7.32
- Resistance Level
- FGI $0.85
- RNAZ $8.48
- Average True Range (ATR)
- FGI 0.08
- RNAZ 0.58
- MACD
- FGI -0.01
- RNAZ 0.41
- Stochastic Oscillator
- FGI 30.00
- RNAZ 70.77
About FGI FGI Industries Ltd.
FGI Industries Ltd is a supplier of kitchen and bath products. The company is business to business supplier of bath and kitchen products to large retail, wholesale, commercial, and specialty channel customers around the globe. The company offers products that fall into four categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The company generates the majority of its revenue from the sale of Sanitaryware products. Geographically, the company generates the majority of its revenue from the United States, followed by Canada and Europe.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.